Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kestra Medical Technologies Ltd. ( (KMTS) ) has shared an update.
Kestra Medical Technologies, Ltd. held its 2025 annual general meeting of shareholders on September 3, 2025, where significant decisions were made regarding the company’s governance and financial oversight. The shareholders elected Conor Hanley and Elizabeth Kwo as Class I directors until the 2028 annual meeting, ratified PricewaterhouseCoopers as the independent registered public accounting firm for the fiscal year ending April 30, 2026, and approved the 2025 Employee Stock Purchase Plan.
The most recent analyst rating on (KMTS) stock is a Hold with a $15.50 price target. To see the full list of analyst forecasts on Kestra Medical Technologies Ltd. stock, see the KMTS Stock Forecast page.
Spark’s Take on KMTS Stock
According to Spark, TipRanks’ AI Analyst, KMTS is a Neutral.
Kestra Medical Technologies Ltd. faces significant challenges with profitability and valuation, as reflected in its negative P/E ratio and lack of dividend yield. Despite strong revenue growth and some improvements in cash flow, the stock’s technical indicators suggest bearish momentum. The company’s financial performance is the most significant factor, highlighting the need for improved operational efficiency to achieve profitability.
To see Spark’s full report on KMTS stock, click here.
More about Kestra Medical Technologies Ltd.
Average Trading Volume: 353,029
Technical Sentiment Signal: Strong Sell
Current Market Cap: $827.7M
See more insights into KMTS stock on TipRanks’ Stock Analysis page.